A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
Titel:
A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors
Auteur:
Doi, Toshihiko Shitara, Kohei Kojima, Takashi Yoshino, Takayuki Dontabhaktuni, Aruna Rebscher, Hans Tang, Shande Cosaert, Jan Ohtsu, Atsushi